media – Page 589 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Surgical Device Company Virtual Incision Raises $18 Million in Series B

Virtual Incision’s RASD weighs just two pounds and is designed to perform the procedure through a smaller incision, potentially reducing recovery time and mitigating the risk of surgical complications.
- Source: xtalks
- 568
- December 18, 2017
FDA medical device RASD Series
Atlas and OrbiMed back Boston’s Kyn in $49M round to pursue immunometabolism therapies

Kyn is led by an Atlas entrepreneur-in-residence Mark Manfredi, who was previously chief scientific officer at Raze Therapeutics (also an Atlas-funded startup). Raze raised a $24 million Series A in 2014, but the company appears to have wound down pretty quickly. The website is no longer active, and Manfredi said Raze still has some assets and collaborations, but no longer employs anyone. Atlas’ Bruce Booth says the underlying cancer metabolism biology was too complicated to warrant further investment. Before Raze, Manfredi was VP of oncology biology at Takeda.
- Source: Endpts
- 509
- December 18, 2017
cancer immunometabolism Market Views Series
Chi-Med Initiates Fruquintinib U.S. Clinical Trials

Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated the United States Phase I bridging clinical trial of fruquintinib. Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors (“VEGFR”) 1, 2 and 3, that has met its primary endpoint in several Phase II and III clinical trials in China for the treatment of colorectal, lung and gastric cancers. The clinical study in the U.S. is a multi-center, open-label, Phase I clinical study to evaluate the safety, tolerability and pharmacokinetics of fruquintinib in U.S. patients with advanced solid tumors. The first drug dose was administered earlier this month. Additional details about this study may be found at clinicaltrials.gov, using identifier NCT03251378.
- Source: chi-med
- 669
- December 18, 2017
cancer Clinical Trials Fruquintinib
Medimetriks Pharmaceuticals, Inc. Receives FDA Approval for Xepi (ozenoxacin) Cream, 1%, a Novel Topical Antibiotic for Impetigo

Medimetriks Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Xepi (ozenoxacin) Cream, 1%, a new chemical entity for the treatment of impetigo in patients two months of age and older when applied topically twice daily for 5 days. In the U.S., impetigo is estimated to account for approximately 10% of skin problems observed in pediatric clinics and is considered the most common bacterial skin infection.
- Source: drugs
- 657
- December 18, 2017
FDA impetigo New Approvals skin problems Xepi (ozenoxacin) Cream
New research examines ADHD medications in pregnancy and risk of birth defects

New US research has found a link between taking certain medications for Attention Deficit Hyperactivity Disorder (ADHD) during pregnancy and an increased risk of birth defects in children.
- Source: drugdu
- 478
- December 18, 2017
ADHD Researches
Check out these 6 simple Google tricks to streamline your search!

Google has become as much of a necessity to modern life as eating.Google’s search is a learning curve and odd one, too. WeYou use it every day, but very few of us actually use it to its full potential. With that being said, the search engine has plenty of tricks up its sleeve. If you want to streamline your search, it’s time to start implementing these 6 simple Google tricks.
- Source: Ddu
- 1,040
- December 15, 2017
Ddu College Google
How to Avoid Being Blocked

Social media has become one of biggest marketing tools on the Internet with Facebook being at the forefront of this marketing revolution. There are however, guidelines and policies on how to use Facebook and when these are violated, you stand the chance of having your account blocked.
- Source: Ddu
- 1,166
- December 15, 2017
Ddu College Facebook
Artificial Organs — We’re Entering an Era Where Transplants Are Obsolete

Around the world, lists of patients in need of an organ transplant are often longer than the lists of those willing (and able) to donate — in part because some of the most in-demand organs for transplant can only be donated after a person has died. By way of example, recent data from the British Heart Foundation (BHF) showed that the number of patients waiting for a heart transplant in the United Kingdom has grown by 162 percent in the last ten years.
- Source: futurism
- 475
- December 15, 2017
heart Researches transplant
Magnetically Guided Bacteria Move Confidently Within Strong Currents, May Soon Deliver Drugs Inside Body

Researchers at Queen’s University in Canada have managed to get a special type of bacteria to swim against a strong current, opening up the possibility of using the organisms as drug delivery vehicles. The team is using magnetotactic bacteria which have magnetic crystals within them and naturally orient themselves with the Earth’s magnetic field. By setting up the external magnetic field, the researchers were able to coax the bacteria to move in predictable ways and directions.
- Source: medgadget
- 426
- December 15, 2017
bacteria magnetotactic Researches
Here’s where ‘Smart Hospitals’ will make big tech investments in the near future

Most U.S. hospitals have a broad portfolio of digital technologies already in place and other innovations in early development or deployment stages, but far fewer qualify as so-called smart hospitals.
- Source: healthcareitnews
- 549
- December 15, 2017
Clinical digital Market Views

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.